NOMOS Corporation’s Peregrine Radiation Dose Calculation System Approved for Marketing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

SEWICKLEY, Pennsylvania-The FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patient’s CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.

SEWICKLEY, Pennsylvania—The FDA has granted NOMOS Corporation clearance to market the Peregrine Monte-Carlo-based radiation dose calculation system, licensed from the Lawrence Livermore National Laboratory where it was developed. Peregrine is a computer-based system for quick calculation, in three dimensions, of radiation doses for use with complex intensity-modulated radiotherapy treatment plans. Monte Carlo is a mathematical technique that simulates the trillions of radiation particles that enter the body during treatment. It selects a random sample of these particles and tracks them through a computer model of the radiation-delivery device and the patient’s CT scans to create a detailed map of the dose distribution (see image). NOMOS will initially incorporate Peregrine into its CORVUS inverse treatment planning system, and will then develop a stand-alone version to work with other treatment planning systems.

Articles in this issue
Joe & Ali Torre Lead ‘Two Against One’ Prostate Cancer Campaign
Efforts to Reduce Tobacco Deaths May Fail in the Short Term
Data Published for First-Line Irinotecan
Manufacturing Capability a Factor in Success of New Biologics
Report Finds States Not Using Tobacco Funds for Prevention
NCI Intramural Program Challenged to ‘Reinvent Itself’
Cisplatin/Irinotecan Offers Survival Advantage in Stage IV Non–Small-Cell Lung Cancer
Surgery Supported for Recurring Colorectal Cancer
Breast Cancer Stamp Funds $6.7 Million in 2-Year NCI Grants
Human Side of Cancer Offers Insights on Coping With the Disease
Irinotecan/Etoposide Combination Achieves 65% Overall Response Rate
Rituximab More Effective in B-Cell NHL Than in MCL
Maternal Diet May Affect Child’s Cancer Risk, Studies Show
Carboplatin and Epirubicin Combination May Offer Less Toxic Alternative for Treating Small-Cell Lung Cancer
Early HDC Improves Survival in Infants With Acute Leukemia
Recent Videos
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Related Content
Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC

Atezolizumab After Chemoradiotherapy Elicits Promising Responses in ESCC

Tim Cortese
March 22nd 2025
Article

In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Most recently, the FDA accepted a second NDA for camrelizumab/rivoceranib as a treatment for patients with unresectable HCC in October 2024.

FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma

Roman Fabbricatore;Russ Conroy
March 21st 2025
Article

The complete response letter for camrelizumab/rivoceranib for patients with advanced HCC did not specify what deficiencies regulators found.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
March 21st 2025
Article

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Ariana Pelosci
March 20th 2025
Article

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.